What happened, in summary

Evelyn was diagnosed with Stage IV ovarian cancer on October 17, 2022, after months of abdominal swelling, fatigue, and other changes she had initially attributed to menopause. She began chemotherapy on November 2 and approached treatment by asking detailed questions and building a support system around herself.

After 4 chemotherapy treatments, Evelyn underwent surgery and then completed the remaining chemotherapy. She described the surgery as successful and said her final scan in May 2023 was unremarkable. Tumor testing later showed that her cancer was HRD-positive, a result that made her eligible for a PARP inhibitor.

Evelyn started Lynparza in June 2023 as maintenance therapy and continued it for 2 years. She experienced joint pain and fatigue but remained committed to treatment. Looking back, she emphasized how biomarker testing changed her options and helped her understand why an additional therapy was being recommended. Her story highlights the value of asking about tumor testing early and using the results to guide treatment decisions.